CancerDrs

Pancreatic Cancer clinical trials in Connecticut

26 actively recruiting pancreatic cancer trials at 18 sites across Connecticut.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …

Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Connecticut:
  • Danbury Hospital — Danbury, Connecticut
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Connecticut:
  • Stamford Hospital/Bennett Cancer Center — Stamford, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…

Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Connecticut:
  • Yale University (Adults and Pediatrics) — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2…

Sponsor: RayzeBio, Inc.
NCT ID: NCT05477576
Sites in Connecticut:
  • Research Facility — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…

Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Connecticut:
  • Ohio State University-Telemedicine — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

The purpose of this study is to evaluate the efficacy and safety of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in partici…

Sponsor: Genentech, Inc.
NCT ID: NCT05968326
Sites in Connecticut:
  • St. Francis Hospital and Medical Center — Hartford, Connecticut
  • Smilow Cancer Center — New Haven, Connecticut
  • Yale Cancer Center — New Haven, Connecticut
  • Smilow Cancer Hospital Care Center at Trumbull — Trumbull, Connecticut
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Connecticut:
  • Hartford Hospital (site 210) — Hartford, Connecticut
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab

This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and in combinat…

Sponsor: Linnaeus Therapeutics, Inc.
NCT ID: NCT04130516
Sites in Connecticut:
  • Yale Cancer Center — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper ga…

Sponsor: Yale University
NCT ID: NCT07282912
Sites in Connecticut:
  • Smilow Cancer Center — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticance…

Sponsor: Pfizer
NCT ID: NCT07090499
Sites in Connecticut:
  • Smilow Cancer Hospital - Yale New Haven Health — New Haven, Connecticut
  • Yale - New Haven Hospital - Yale Cancer Center — New Haven, Connecticut
  • Smilow Cancer Hospital Phase 1 Unit — New Haven, Connecticut
  • Smilow Cancer Hospital - Trumbull — Trumbull, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT ID: NCT06917079
Sites in Connecticut:
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expr…

Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07360314
Sites in Connecticut:
  • Yale University - Yale University School of Medicine — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors

The purpose of this first-in-human study is to identify a recommend dose(s) for subsequent larger studies (recommended dose(s) for expansion, RDE), examining increasing doses of M0324, primarily looking at safety, but also preliminary sign…

Sponsor: EMD Serono Research & Development Institute, Inc.
NCT ID: NCT07166601
Sites in Connecticut:
  • Yale University School of Medicine — New Haven, Connecticut
View on ClinicalTrials.gov →
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Connecticut:
  • Veterans Affairs Connecticut Healthcare System-West Haven Campus — West Haven, Connecticut
View on ClinicalTrials.gov →
Recruiting Network

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers

The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in Connecticut:
  • Smilow Cancer Hospital-Derby Care Center — Derby, Connecticut
  • Smilow Cancer Hospital Care Center-Fairfield — Fairfield, Connecticut
  • Smilow Cancer Hospital Care Center at Glastonbury — Glastonbury, Connecticut
  • Smilow Cancer Hospital Care Center at Greenwich — Greenwich, Connecticut
  • Smilow Cancer Hospital Care Center - Guilford — Guilford, Connecticut
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Connecticut:
  • Massive Bio SYNERGY-AI site — Hartford, Connecticut
  • Massive Bio SYNERGY-AI site — Norwalk, Connecticut
View on ClinicalTrials.gov →
Recruiting Academic/Other

Pancreatic Cancer Early Detection Consortium

The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individ…

Sponsor: Arbor Research Collaborative for Health
NCT ID: NCT04970056
Sites in Connecticut:
  • Yale University — New Haven, Connecticut
View on ClinicalTrials.gov →
Phase 4 Recruiting Industry

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years

This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x…

Sponsor: Guerbet
NCT ID: NCT04373564
Sites in Connecticut:
  • Yale University School of Medicine — New Haven, Connecticut
View on ClinicalTrials.gov →
Recruiting Academic/Other

Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

The study schema is shown in Figure 4. (A) All patients referred to one of the participating academic centers for EUS evaluation of the PCL will be enrolled in the protocol if they satisfy inclusion criteria. Patient consent will be obtain…

Sponsor: Ohio State University Comprehensive Cancer Center
NCT ID: NCT03492151
Sites in Connecticut:
  • Yale School of Medicine — New Haven, Connecticut
View on ClinicalTrials.gov →
Recruiting Academic/Other

A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus

The main goal of this study is to explore the relationship between new-onset diabetes mellitus/deteriorating diabetes and a subsequent diagnosis of pancreatic cancer. Magnetic Resonance Imaging and Magnetic cholangiopancreatography (MRI/MR…

Sponsor: Nuvance Health
NCT ID: NCT03937453
Sites in Connecticut:
  • Yale University — New Haven, Connecticut
  • Nuvance Health — Norwalk, Connecticut
View on ClinicalTrials.gov →

Showing 25 of 26 trials with sites in Connecticut. See all pancreatic cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07